Environmental Enrichment Intervention and Brain Development in Preterm Infants
PRE-ENV
A Prospective Study Investigating the Effects of an Environmental Enrichment-Based Intervention on Brain Development in Preterm Infants
2 other identifiers
interventional
28
1 country
1
Brief Summary
This study aims to evaluate the effects of a structured environmental enrichment (EE)-based early developmental intervention on brain, motor, and cognitive outcomes in preterm infants. Infants born before 37 weeks of gestation are at increased risk for alterations in structural and functional brain development, which may be further influenced by the neonatal intensive care environment, including exposure to excessive light, noise, and frequent medical procedures. The intervention is a prospectively implemented, home-based developmental program structured according to the HEP (Homeostasis-Enrichment-Plasticity) approach, providing enriched sensory-motor experiences, environmental novelty, problem-solving activities, and opportunities for active exploration. The program is delivered through guided parental involvement with support from trained therapists, according to a predefined protocol. Developmental outcomes will be assessed at baseline and after the intervention period using standardized, non-invasive assessment tools. The intervention does not include any pharmacological treatment or medical device. This study evaluates whether participation in an EE-based early developmental intervention leads to improved neurodevelopmental outcomes in preterm infants.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jan 2026
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 21, 2025
CompletedFirst Posted
Study publicly available on registry
January 15, 2026
CompletedStudy Start
First participant enrolled
January 15, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 30, 2026
January 15, 2026
January 1, 2026
6 months
November 21, 2025
January 6, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Motor Development Assessed by Bayley Scales of Infant and Toddler Development, Third Edition (Bayley-III)
Motor development will be assessed using the Bayley Scales of Infant and Toddler Development, Third Edition (Bayley-III), Motor Composite Score, which evaluates fine and gross motor development. The Motor Composite Score ranges from 40 to 160, with higher scores indicating better motor development.
Baseline (corrected age of 1 month) and 12 weeks (end of intervention)
Motor Performance Assessed by Test of Infant Motor Performance (TIMP)
Motor performance will be assessed using the Test of Infant Motor Performance (TIMP), which evaluates postural and selective control of movement in young infants. The TIMP total score ranges from -49 to 142, with higher scores indicating better motor performance.
Baseline (corrected age of 1 month) and 12 weeks (end of intervention)
Secondary Outcomes (7)
Cognitive Development Assessed by Bayley Scales of Infant and Toddler Development, Third Edition (Bayley-III)
Baseline (corrected age of 1 month) and 12 weeks (end of intervention)
Brain Morphometric Measurements Assessed by Cranial Ultrasound Imaging
Baseline (corrected age of 1 month) and 12 weeks (end of intervention)
Urinary Concentration of Brain-Derived Neurotrophic Factor (BDNF)
Baseline (corrected age of 1 month) and 12 weeks (end of intervention)
Urinary Concentration of Nerve Growth Factor (NGF)
Baseline (corrected age of 1 month) and 12 weeks (end of intervention)
Urinary Concentration of Tau Protein
Baseline (corrected age of 1 month) and 12 weeks (end of intervention)
- +2 more secondary outcomes
Study Arms (2)
Control Group
ACTIVE COMPARATORInfants in this group will receive conventional developmental therapy and routine medical follow-up as provided within standard clinical practice. This approach represents an active comparator and does not include the structured environmental enrichment or the Homeostasis-Enrichment-Plasticity (HEP)-based intervention used in the experimental group. Participants in this group will undergo the same study-related assessments as the intervention group at baseline and after 12 weeks.
HEP Home-Practice Group:
EXPERIMENTALA structured environmental enrichment-based developmental intervention delivered over a 12-week period. The program is based on the Homeostasis-Enrichment-Plasticity (HEP) framework and includes age-appropriate sensory-motor activities, environmental novelty, problem-solving opportunities, and active caregiver-infant interaction. The intervention is delivered through weekly therapist-guided sessions, with caregivers encouraged to continue the practices at home as part of daily care.
Interventions
Environmental enrichment-based program applied for 12 weeks, including sensory-motor stimulation, environmental novelty, problem-solving tasks, and active exploration with caregivers.
Standard developmental care and routine medical follow-up provided within usual clinical practice. This care reflects established developmental support approaches typically offered to preterm infants and does not include structured environmental enrichment or the Homeostasis-Enrichment-Plasticity (HEP)-based intervention applied in the experimental group.
Eligibility Criteria
You may qualify if:
- Preterm infants born before 37 completed weeks of gestation.
- Corrected age between 4 and 7 weeks at the time of enrollment.
- Medically stable, as confirmed by the attending neonatologist
- Written informed consent obtained from parents or legal guardians.
You may not qualify if:
- Major congenital anomalies or known genetic syndromes.
- Severe intraventricular hemorrhage (Grade III-IV) or other major neurological impairment.
- Unstable medical conditions that would interfere with safe participation in the study procedures.
- Caregivers unable to attend scheduled study sessions or comply with study-related procedures.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Tuğçe Altıok Physical Therapy Center
Nilufer, Bursa, 16110, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Tuğçe Altıok, PhD
Eskisehir Osmangazi University, Institute of Health Sciences
- PRINCIPAL INVESTIGATOR
Ferruh Yücel, Professor, PhD
Eskisehir Osmangazi University
- STUDY DIRECTOR
Aymen Balıkçı, PT, PhD
Aymen Balıkçı Physical Therapy Clinic
- STUDY DIRECTOR
Teresa A. May-Benson, PhD
Teresa A. May-Benson Therapy Clinic
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- PhD Candidate
Study Record Dates
First Submitted
November 21, 2025
First Posted
January 15, 2026
Study Start
January 15, 2026
Primary Completion (Estimated)
June 30, 2026
Study Completion (Estimated)
July 30, 2026
Last Updated
January 15, 2026
Record last verified: 2026-01
Data Sharing
- IPD Sharing
- Will not share
Individual participant data (IPD) will not be shared.